Advertisement
×
Upcoming Site Maintenance on Tuesday, May 28, 2024: Please note that some site functionality such as new user registrations, updates to user accounts, and article purchases will be unavailable during maintenance on this date.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Dec 2019

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

View All Author Information

Purpose:

We investigated the impact of previous, simultaneous or subsequent bladder cancer on the clinical outcomes of upper urinary tract urothelial carcinoma.

Materials and Methods:

We retrospectively collected data on 2,668 patients who underwent radical nephroureterectomy of nonmetastatic upper urinary tract urothelial carcinoma in 1995 to 2009. We evaluated the impact of bladder cancer on overall mortality and the factors predictive of subsequent bladder cancer.

Results:

A total of 631 patients (23.7%) had previous or simultaneous bladder cancer. Patients with previous or simultaneous bladder cancer had significantly shorter overall survival than patients without previous or simultaneous bladder cancer (HR 1.29, 95% CI 1.09-1.53, p=0.0026). Of the 2,037 patients without previous or simultaneous bladder cancer 683 (33.5%) subsequently had bladder cancer after radical nephroureterectomy. Of patients with pT0-2 disease those with subsequent bladder cancer had significantly shorter overall survival than patients without subsequent bladder cancer (HR 1.81, 95% CI 1.23-2.67, p=0.0025). In patients with pT3-4 disease subsequent bladder cancer was not associated with worse overall survival. On multivariable analyses independent predictors of subsequent bladder cancer were gender, preoperative urine cytology and clinical node status in the preoperative setting, and gender, adjuvant chemotherapy and pathological node status in the postoperative setting.

Conclusions:

Bladder cancer was significantly associated with worse clinical outcomes after radical nephroureterectomy of upper urinary tract urothelial carcinoma. Preventing subsequent bladder cancer in patients with pT0-2 upper urinary tract urothelial carcinoma may lead to better prognosis in those who undergo radical nephroureterectomy.

References

  • 1. : Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000; 164: 1523. LinkGoogle Scholar
  • 2. : Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003; 170: 1151. LinkGoogle Scholar
  • 3. : Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013; 189: 1214. LinkGoogle Scholar
  • 4. : Effects of previous or synchronous non-muscle invasive bladder cancer on clinical results after radical nephroureterectomy for upper tract urothelial carcinoma: a multi-institutional study. Urol J 2015; 12: 2233. Google Scholar
  • 5. : Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol Oncol 2013; 31: 1615. Google Scholar
  • 6. : Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol 2014; 32: 23 e1. Google Scholar
  • 7. : Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol 2013; 31: 1643. Google Scholar
  • 8. : Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol 2013; 31: 61. Google Scholar
  • 9. : A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015; 67: 1122. Google Scholar
  • 10. : Clinical implications of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol 2016; 23: 378. Google Scholar
  • 11. : Bladder recurrence after radical nephroureterectomy: predictors and impact on oncological outcomes. Int J Urol 2013; 20: 1078. Google Scholar
  • 12. : Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. World J Urol 2017; 35: 1737. Google Scholar
  • 13. : The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471. Google Scholar
  • 14. : Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol 2001; 165: 672. LinkGoogle Scholar
  • 15. : Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005; 11: 6512. Google Scholar
  • 16. : Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol 2004; 172: 2177. LinkGoogle Scholar
  • 17. : Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. World J Urol 2015; 33: 1005. Google Scholar
  • 18. : Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol 2012; 30: 252. Google Scholar
  • 19. : Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60: 703. Google Scholar
  • 20. : Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013; 31: 1422. Google Scholar
  • 21. : Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urol 2001; 8: 212. Google Scholar
  • 22. : Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis. J Buon 2015; 20: 1229. Google Scholar
  • 23. : Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 2017; 35: 852. Google Scholar
  • 24. : NCCN guidelines insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 1041. Google Scholar
  • 25. : European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73: 111. Google Scholar
  • 26. : The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 2014; 32: 48. Google Scholar
  • 27. : Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008; 15: 800. Google Scholar
  • 28. : Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 2014; 65: 650. Google Scholar

The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.

Supported in part by the National Cancer Center Research and Development Fund (23-A-20, 26-A-4, 29-A-3) and JSPS KAKENHI Grant No. JP16K11010.

No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article.

Advertisement